Clearside Biomedical Faces Nasdaq Delisting Warning

TL;DR

Nasdaq is kicking Clearside out, company looking for options.

AI Summary

Clearside Biomedical, Inc. announced on February 7, 2025, that it received a notification from The Nasdaq Stock Market indicating a failure to meet continued listing requirements. The company is currently evaluating its options to regain compliance.

Why It Matters

This notification suggests potential financial distress or operational challenges for Clearside Biomedical, which could impact its stock value and ability to raise capital.

Risk Assessment

Risk Level: high — Receiving a delisting notice from a major stock exchange like Nasdaq indicates significant non-compliance with listing standards, posing a substantial risk to the company's public trading status.

Key Players & Entities

• Clearside Biomedical, Inc. (company) — Registrant
• The Nasdaq Stock Market (company) — Listing Exchange

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
• $1.00 — he Company's common stock was less than $1.00 per share for the previous 30 consecuti
• $5,000 — to submit a Transfer Application and a $5,000 application fee. In addition, the Compa

Filing Documents

• clsd-20250207.htm (8-K) — 44KB
• 0000950170-25-019866.txt ( ) — 155KB
• clsd-20250207.xsd (EX-101.SCH) — 24KB
• clsd-20250207_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 7, 2025, Clearside Biomedical, Inc. (the " Company ") received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (" Nasdaq ") notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market, as the minimum bid price of the Company's common stock was less than $1.00 per share for the previous 30 consecutive business days. The notice has no present impact on the listing of the Company's securities on the Nasdaq Global Market. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until August 6, 2025, to regain compliance. To regain compliance, during this 180-day compliance period, the Company's minimum bid price of listed securities must close at $1.00 per share or more for a minimum of 10 consecutive business days. In the event that the Company does not regain compliance with the Nasdaq Listing Rules prior to the expiration of the 180-day compliance period, the Company may be eligible for additional time to regain compliance pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(ii) by transferring to the Nasdaq Capital Market. To qualify, the Company would need to submit a Transfer Application and a $5,000 application fee. In addition, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement. In addition, the Company would need to provide written notice to Nasdaq of its intention to cure the minimum bid price deficiency during the second compliance period by effecting a reverse stock split, if necessary. As part of its review process, the Nasdaq staff will make a determination of whether it believe

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 13, 2025 CLEARSIDE BIOMEDICAL, INC. By: /s/ Charles A. Deignan Name: Charles A. Deignan Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR